Myriad Genetics MYGN U.S. — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Myriad Genetics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Myriad Genetics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Myriad Genetics's u.s. — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Myriad Genetics's U.S. — revenue?
- Myriad Genetics (MYGN) reported U.S. — revenue of $187M in Q1 2026.
- How has Myriad Genetics's U.S. — revenue changed year-over-year?
- Myriad Genetics's U.S. — revenue increased by 3.0% year-over-year, from $181.6M to $187M.
- What is the long-term trend for Myriad Genetics's U.S. — revenue?
- Over 4 years (2021 to 2025), Myriad Genetics's U.S. — revenue has grown at a 6.2% compound annual growth rate (CAGR), from $603.7M to $768M.
- What does U.S. — revenue mean?
- This metric represents the total gross sales generated from diagnostic testing services and products provided within the United States market. It serves as a primary indicator of the company's domestic market penetration, adoption of its molecular diagnostic panels, and the overall scale of its core commercial operations. Tracking this figure helps investors evaluate the performance of the company's primary geographic revenue stream and its ability to capture market share in the domestic healthcare sector.